compounded semaglutide enforcement news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Safe use of compounded GLP

Potent Peptide and Extract Blend: Our formula boasts a dynamic combination of skin-loving ingredients, including Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7, and Phaseolus Lunatus (Green Bean) Extract

Projected Milestones Important: Unless noted as "confirmed," the dates below are analyst projections based on Lilly's public statements and typical regulatory timelines

Concurrently, the percentage of patients who were prescribed a GLP-1 drug and had only an overweight or obesity diagnosis increased from 3.7 percent in 2019 to 16.5 percent in 2024, a 344.4 percent rise

SU therapy was stopped at randomisation, and 12% of patients were receiving a thiazolidinedione (TZD)